Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan).
Takeshi YamashitaYukihiro KoretsuneTomoko NagaoKazuhito ShiosakaiPublished in: Journal of arrhythmia (2021)
These results provide real-world evidence for the long-term good safety and effectiveness profile of edoxaban in Japanese NVAF patients under clinical practice.
Keyphrases
- atrial fibrillation
- clinical practice
- end stage renal disease
- randomized controlled trial
- systematic review
- oral anticoagulants
- venous thromboembolism
- ejection fraction
- direct oral anticoagulants
- newly diagnosed
- chronic kidney disease
- heart failure
- public health
- catheter ablation
- prognostic factors
- peritoneal dialysis
- percutaneous coronary intervention
- patient reported outcomes
- patient reported